John Nicols
As President & CEO since June 2012, John has lead the turnaround and growth of Codexis, the Nasdaq-listed protein engineering company (Ticker: CDXS). Prior to Codexis, John worked in various leadership roles for more than 22 years at Albemarle Corporation, a maker of highly engineered specialty chemicals. MBA from MIT Sloan; BS Chemical Engineering from NYU/Poly; Native of New York city.
Organicols
Infrastructure Investments for Accelerating the Bioeconomy
-
In this session, we'll discuss the pivotal role of infrastructure investments in accelerating the bioeconomy. Harnessing the full potential of synthetic biology requires access to expensive infrastructure for biomanufacturing and scale-up. We'll dive into how investors, CMOs, and startups are capitalizing on this opportunity space to accelerate bringing products to market.
